Find Neurology Drugs in Phase III Clinical Development in UNITED KINGDOM

Lead Product(s): Remimazolam

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals N.V.

Deal Size: $143.2 million Upfront Cash: $11.1 million

Deal Type: Licensing Agreement January 09, 2020

Details:

Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.